ITGA2B and non-small cell lung carcinoma: While the optimal cutoff value (0.001749) of platelet-ITGA2B mRNA was used to categorize NSCLC patients into high-level or low-level group, χ2 tests showed that there were no differences in clinicopathologic parameters including histological type between patients with NSCLC and platelet-ITGA2B mRNA overall (all at p > 0.05 except smoking status in validation cohort, Table S5 and Figure S10).